Good news:
Fresh blood. Fresh thinking. Big hitters onboarded and continue to speak to and add KOLs. COH collaboration on the cards - non-trivial IMO.
Scientific papers, conference preso's and comms all putting us on the radar "bringing bisantrene squarely before big pharma's stakeholders" as DCB put it. He is delivering per the brief. With gusto! I don't have complaints.
IV formulation behind schedule... never easy to deliver scientific outcomes per project plans. Not great, but reality of life.
Clinical update- I would expect to see it no later than end of July when the quarterly is due if not sooner.
July/ August is the big strategy unveiling which will need another 6-12 months to play out while the clinical outcomes should keep us interested.
AIMO. No advice.
Ann: Letter to Shareholders, page-16
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |